Research-grade peptides, with proof behind every lot.

Triple GIP/GLP-1/glucagon receptor agonist research peptide · 15mg

Research context: Retatrutide is an investigational triple agonist (GIP, GLP-1, glucagon receptors) developed by Eli Lilly — not yet FDA-approved for any indication. A 2023 phase 2 trial published in the New England Journal of Medicine reported mean weight reduction of up to 24.2% at 48 weeks in the highest-dose group, alongside improvements in liver fat, blood pressure, and lipid markers in that trial population. Phase 3 trials are ongoing as of 2026. These are clinical trial findings in a controlled pharmaceutical development program, not results attributable to this or any unapproved research material.

TB-500 · BPC-157 · GHK-Cu combination research peptide

Research context: TB-500 and BPC-157 are synthetic peptides studied mainly in animal and in-vitro models of wound and connective-tissue repair; human data is limited to a small number of early trials (e.g., topical thymosin beta-4 in dermal ulcers and corneal injury) and is not sufficient to establish safety or effect in humans. Neither compound is FDA-approved for any use — BPC-157's regulatory classification for pharmacy compounding has changed multiple times since 2023 and remains unsettled. GHK-Cu has a larger body of human dermatological research, mainly in topical/cosmetic contexts studying skin remodeling and collagen activity. This information reflects the published literature, not outcomes for this product.

Mitochondrial-derived peptide, metabolic research · 10mg

Research context: MOTS-c is a mitochondrial-derived peptide studied as an "exercise mimetic" — research in mice has linked it to improved insulin sensitivity, fat metabolism, and physical capacity, and human studies have measured MOTS-c rising sharply in blood and muscle after exercise. Clinical development in humans has been limited so far, partly due to the peptide's short half-life and delivery challenges. It is not FDA-approved and has no established human dosing or safety profile.

Coenzyme, cellular energy metabolism research · 500mg

Research context: NAD+ is a coenzyme with a well-established role in cellular energy metabolism and mitochondrial function — this basic biochemistry is not in dispute. What remains actively studied and debated is whether supplementing NAD+ or its precursors produces measurable benefits in humans; existing human trials are mostly small and focus on NAD+ precursors (like NR or NMN) rather than NAD+ itself, with mixed results. No confirmed therapeutic benefit in humans has been established for direct NAD+ administration.

GHRH analog + selective GH secretagogue research stack

Research context: CJC-1295 (a GHRH receptor agonist) and Ipamorelin (a selective ghrelin-receptor/GHS-R1a agonist) act on separate receptor pathways involved in growth hormone secretion. Preclinical research pairing the two has reported larger, more pulsatile GH and downstream IGF-1 elevations than either compound produces alone, which is the basis for studying them together in GH-axis research models. Neither compound is FDA-approved for any human use.

TB-500 · BPC-157 combination research peptide

Research context: TB-500 and BPC-157 are synthetic peptides studied mainly in animal and in-vitro models of wound and connective-tissue repair; human data is limited to a small number of early trials and is not sufficient to establish safety or effect in humans. Neither compound is FDA-approved for any use — BPC-157's regulatory classification for pharmacy compounding has changed multiple times since 2023 and remains unsettled. This information reflects the published literature, not outcomes for this product.

GHRH analog research peptide · 10mg

Research context: Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. Two phase 3 placebo-controlled trials in HIV patients with lipodystrophy (816 participants total) showed statistically significant reductions in visceral adipose tissue and waist circumference, leading to its narrow FDA approval in 2010. Outside that specific approved indication and formulation, tesamorelin has no other established human use.